ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Discontinuation Rates in Multicenter Trials – Are They Driven by Attitudes or Facts?

B. Nashan1, F. Braun2, D. Dragun3, I. A. Hauser3, P. Schemmer2, H. J. Schlitt2, C. Sommerer3, B. Suwelack3, C. Schiedel4, I. Kroeger4, F. Thaiss3

1Athena and Hephaistos, Study Group, Germany, 2Hephaistos, Study Group, Germany, 3Athena, Study Group, Germany, 4Novartis Pharma GmbH, Nürnberg, Germany

Meeting: 2020 American Transplant Congress

Abstract number: B-107

Keywords: Immunosuppression, Kidney/liver transplantation, Outcome

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The ATHENA [NCT01843348] and Hephaistos [NCT01551212] trials were designed to compare everolimus [EVR] in combination with reduced tacrolimus [rTAC] or reduced cyclosporine A [rCyA] vs. a standard regimen of mycophenolic acid [MPA] and TAC in de novo kidney transplant [KTx] recipients, and EVR plus rTAC vs. TAC alone in de novo liver transplant [LTx] recipients, respectively. As it has often been claimed that treatment discontinuation rates due to AEs are higher with EVR than with conventional regimes, discontinuation rates in these 2 studies were analyzed.

*Methods: Both studies were 12M prospective, open-label multicenter trials. ATHENA included 612 patients [pts] in Germany and France, randomized at time of KTx to EVR/rTAC, EVR/rCyA or TAC/MPA. In HEPHAISTOS, 333 pts were randomized between day 7-21 after LTx to EVR/rTAC or TAC alone, all with steroids until M6.

*Results: All discontinuation and adjustment rates are shown in Table 1. No AE-specific correlation was detected for either, indicating no specific drug related reason for discontinuation or adjustment. Interestingly, the incidence of total discontinuation rates was contrary between EVR and control arms in both studies. Moreover, rates of study drug discontinuation in ATHENA varied widely between centers (0-100%, 0-100% and 0-60% in the EVR/rCyA, EVR/rTAC and TAC/MPA groups, respectively), while variations were less in Hephaistos (0-53% EVR/TAC and 0-62% TAC group).

*Conclusions: Both, ATHENA and HEPHAISTOS, confirmed the safe and effective use of EVR with rTAC or rCyA in KTx and LTx. However, the most striking finding of this analysis was the inverse incidence of discontinuation rate in control vs treatment arms between the KTx and LTx studies. Further, AE analysis revealed no specific drug related reasons for discontinuations in general, yet showed significant differences between not only organs but also centers. These interesting findings are so far unexplained, but we hypothesize, that attitudes driven by investigators’ background and/or experience play a role and this might aid in understanding the results and differences observed in multicenter clinical trials.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nashan B, Braun F, Dragun D, Hauser IA, Schemmer P, Schlitt HJ, Sommerer C, Suwelack B, Schiedel C, Kroeger I, Thaiss F. Discontinuation Rates in Multicenter Trials – Are They Driven by Attitudes or Facts? [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/discontinuation-rates-in-multicenter-trials-are-they-driven-by-attitudes-or-facts/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences